---

### 2. TEN INTEGRATED COMPUTATIONAL MODULES (`run_ai4pharm_omnibus_suite.py`)

#### TASK 1: Multi-Parameter Optimization (MPO), ADMETox & Beyond-Rule-of-5 (bRo5) Profiling
- Ingest a curated panel of 30 clinical reference compounds (10 Blockbusters, 10 Toxic/Permeability Dropouts, 10 bRo5 Modalities like Venetoclax and Cyclosporine A).
- Implement continuous desirability scoring: Pfizer CNS-MPO (cLogP, cLogD, MW, TPSA, HBD, pKa) alongside bRo5 chameleonic flexibility metrics ($Fsp^3$, aromatic ring count $\le 3$).
- Evaluate empirical/QSAR surrogate liabilities: Delaney ESOL aqueous solubility, hERG cardiotoxicity risk, Caco-2 $P_{\text{app}}$ membrane permeability, and Human Intestinal Absorption (HIA %).

#### TASK 2: Targeted Protein Degradation (TPD), Ternary Cooperativity & Hook Effect
- Formulate the coupled non-linear mass-action equilibrium equations for total concentrations $[P]_0$ (PROTAC), $[E]_0$ (E3 Ligase), and $[T]_0$ (Target Protein):
  $$[P]_0 = [P] + [EP] + [PT] + [EPT], \quad [E]_0 = [E] + [EP] + [EPT], \quad [T]_0 = [T] + [PT] + [EPT]$$
- Solve for equilibrium ternary complex $[EPT]$ across a 9-order concentration sweep ($10^{-12}\text{ M}$ to $10^{-3}\text{ M}$) under cooperativity regimes $\alpha \in \{0.01, 1.0, 10.0, 100.0\}$.
- Demonstrate the universal biphasic **Hook Effect**, numerically determining $[EPT]_{\max}$ and optimal dosage window $[P]_{\text{opt}} = \sqrt{(K_{D,E} + [E]_0)(K_{D,T} + [T]_0)}$.
- Model linker 3D conformational ensembles (RDKit ETKDGv3) evaluating end-to-end exit vector distance distribution ($r_{E-T}$) and radius of gyration ($R_g$).

#### TASK 3: Covalent Warhead Kinetics, Target Residence Time & GSH Liability
- Model two-step covalent inactivation: $E + I \underset{k_{\text{off}}}{\stackrel{k_{\text{on}}}{\rightleftharpoons}} E \cdot I \stackrel{k_{\text{inact}}}{\longrightarrow} E-I$ across 8 electrophilic warheads (acrylamides, chloroacetamides, vinyl sulfones).
- Solve hyperbolic saturation rate curves $k_{\text{obs}} = k_{\text{inact}}[I] / (K_I + [I])$, extracting covalent efficiency $k_{\text{inact}}/K_I$.
- Model cellular target residence time ($t_R = 1/k_{\text{off}}$) and dynamic washout recovery accounting for target protein resynthesis flux ($k_{\text{syn}}$).
- Simulate off-target Glutathione (GSH, $5\text{ mM}$) conjugation kinetics, calculating $t_{1/2,\text{GSH}}$ and the Therapeutic Safety Margin against drug-induced liver injury (DILI).

#### TASK 4: Whole-Body 7-Compartment PBPK Model & Clinical Dose Titration
- Implement In-Vitro to In-Vivo Extrapolation (IVIVE): Scale human liver microsomal clearance ($\text{CL}_{\text{int,mic}}$) to whole-body hepatic clearance ($\text{CL}_H$) via the Well-Stirred Model ($Q_H = 90\text{ L/h}$).
- Solve the 7-compartment mass-balance ODE system (Blood Plasma, Liver, Gut, Kidney, Brain, Lung, Peripheral Tissues) using Rodgers-Rowland tissue partition coefficients ($K_{p,i}$).
- Simulate single IV bolus vs. single oral dose ($F\%$) vs. 7-day multi-dose BID accumulation regimens.
- Implement an automated clinical dose titration algorithm determining the minimum daily oral dose ($D_{\text{clinical}}$) guaranteeing dynamic free concentration $C_{\text{free}}(t) > \text{IC}_{90}$ for $\ge 90\%$ of the 24-hour interval without exceeding toxic thresholds.

#### TASK 5: CYP450 Drug-Drug Interactions (DDI) & Mechanism-Based Inactivation (MBI)
- Model clinical CYP isoforms (CYP3A4, CYP2D6, CYP2C9) across 6 reference drugs (Ketoconazole, Clarithromycin, Ritonavir, etc.) under both reversible ($K_i$) and irreversible MBI ($k_{\text{inact}}, K_I, k_{\text{deg}}$).
- Calculate static regulatory risk ratios ($R_1, R_2, \text{AUCR}_{\text{net}}$) per FDA/EMA guidance.
- Simulate dynamic PBPK co-administration of perpetrator with clinical probe substrates (Oral Midazolam $2\text{ mg}$ and Metoprolol $50\text{ mg}$), tracking active functional enzyme depletion, victim AUC fold-increase, and post-cessation resynthesis regeneration timelines to $90\%$ baseline.

#### TASK 6: Pharmaceutics & Amorphous Solid Dispersion (ASD) Supersaturation Thermodynamics
- Screen 4 polymeric carriers (HPMC-AS, PVP-VA, Soluplus, Eudragit L100) using partial Hansen Solubility Parameters to derive Flory-Huggins $\chi_{\text{drug-poly}}$ and mixing free energy ($\Delta G_{\text{mix}}$), generating spinodal AAPS boundaries.
- Predict binary dispersion glass transition temperature ($T_{g,\text{mix}}$) via Gordon-Taylor and physical recrystallization induction times ($t_{\text{ind}}$) via Adam-Gibbs / VFT relaxation.
- Formulate coupled non-sink dissolution-precipitation ODEs modeling gastrointestinal luminal conditions ($\text{pH} = 6.8$, FaSSIF):
  $$\frac{dC}{dt} = \frac{D \cdot S(t)}{h}(C_{\text{amorphous}} - C) - k_{\text{precip}}(C - C_{\text{crys}})^n \exp\left( -\frac{\Delta G_{\text{nuc}}}{(k_BT)^3(\ln S)^2} \right)$$
- Demonstrate the "Spring-and-Parachute" supersaturation profile ($> 4\text{ hours}$), dissolution $\text{AUC}$ enhancement, and oral absorption enhancement ratio ($\text{ER}_{\text{abs}}$) vs. unformulated crystalline drug.

#### TASK 7: Quantitative Systems Pharmacology (QSP) Immuno-Oncology Combination Synergy
- Model unperturbed tumor growth transitioning from exponential to linear regimes via the Simeoni TGI framework coupled to 3 non-proliferating apoptotic transit compartments ($w_1, w_2, w_3$).
- Couple small-molecule tumor cell lysis to tumor antigen release flux ($\text{Flux}_{\text{ag}} = w_3/\tau$), host CD8+ cytotoxic T-lymphocyte ($E_{\text{CTL}}$) infiltration, and monoclonal antibody PK/receptor occupancy ($\text{RO}(t) = C_{\text{mAb}} / (K_D + C_{\text{mAb}})$) suppressing T-cell exhaustion.
- Simulate 4 arms over 60 days (Vehicle, Targeted QD, Anti-PD-1 Q2W, Combination), calculating dynamic Excess Over Bliss ($\Delta\text{Bliss}(t)$).
- Execute a virtual clinical trial of 50 heterogeneous oncology patients (incorporating log-normal inter-individual variability in clearance, doubling time, and immune infiltration), generating Kaplan-Meier Progression-Free Survival (PFS) curves and Hazard Ratios.

#### TASK 8: ADC Stochastic Conjugation Kinetics, HIC Analytical Twin & Bystander Diffusion
- Model stochastic interchain cysteine conjugation kinetics (Gillespie / master equations) across 8 available thiol sites of an IgG1 antibody, deriving discrete DAR species fractions ($0$ to $8$) and average weighted $\langle\text{DAR}\rangle$.
- Simulate High-Performance Hydrophobic Interaction Chromatography (HIC) analytical profiles resolving individual DAR peaks based on surface hydrophobicity ($A_{\text{hydrophobic}} \propto \text{DAR}^{1.15}$).
- Formulate non-linear ODEs tracking receptor-mediated endocytosis, lysosomal Cathepsin-B cleavage of Val-Cit linkers, and free cytotoxic payload release.
- Solve 3D radial tissue diffusion PDEs ($r \in [0, 200\text{ }\mu\text{m}]$) modeling the bystander killing of neighboring antigen-negative tumor cells as a function of membrane permeability.

#### TASK 9: Cryo-EM Heterogeneity Latent Manifold, Cryptic Pockets & Allosteric PRS Mapping
- Simulate continuous Cryo-EM single-particle conformational heterogeneity: Project an ensemble of 500 breathing conformers onto a 2D non-linear latent manifold ($z_1, z_2$), computing simulated 3D electron density voxel slices.
- Construct a 5-state Markov State Model (MSM) enforcing detailed balance to reconstruct the Potential of Mean Force (PMF), extracting the thermodynamic cryptic pocket opening penalty ($\Delta G_{\text{open}}$).
- Track transient geometric Pocket Volume ($\text{\AA}^3$) and Druggability Score ($D_{\text{score}}$), pinpointing the transition from an undruggable surface cleft into an induced deep pocket.
- Implement Perturbation Response Scanning (PRS) via Linear Response Theory on the $C_\alpha$ Elastic Network Model Hessian: $\Delta\mathbf{r} = \mathbf{H}^{-1}\mathbf{F}$, tracing the continuous residue allosteric conduit transmitting signals across $> 30\text{ \AA}$ to the active site.

#### TASK 10: RNA-Targeted Small Molecule CADD & Pre-mRNA Splicing Thermodynamics
- Ingest an asymmetric internal bulge loop from an exon-intron 5'-splice site junction (e.g., SMN2/Risdiplam target motif).
- Calculate the base-pairing probability matrix $\mathbf{P}$ and positional Shannon entropy ($H_i$) via the McCaskill dynamic programming partition function, identifying flexible non-canonical bulge residues ($H_i > 1.2\text{ bits}$).
- Featurize 3D A-form RNA major/minor groove dimensions, electrostatic phosphate negative clefts, and purine-purine $\pi$-stacking platforms.
- Model the coupled induced-fit thermodynamic cycle ($K_{D,\text{eff}} = K_D [1 + \exp(\Delta G_{\text{conf}}^\circ / k_BT)]$) across 4 small-molecule chemical scaffolds.
- Formulate mass-action spliceosome (U1 snRNP) recruitment shifting alternative splicing equilibrium, generating pharmacodynamic sigmoidal dose-response curves predicting clinical Exon Inclusion % ($\text{EC}_{50}$, Hill slope).

---

### 3. PUBLICATION-GRADE DELIVERABLES (300 DPI in `./figures_omnibus/`)
Write vectorized code to generate and save 10 multi-panel high-resolution figures:
1. `fig_task1_developability_mpo.png`: CNS-MPO violin plots, 6-axis ADMET radar charts, and bRo5 chemical space.
2. `fig_task2_tpd_hook_effect.png`: Bell-shaped $[EPT]$ curves vs. $\alpha$ factors, 2D sensitivity heatmap, and linker $r_{E-T}$ histograms.
3. `fig_task3_covalent_kinetics.png`: $k_{\text{obs}}$ hyperbola, target recovery post-washout, and GSH on/off-target safety Pareto frontier.
4. `fig_task4_pbpk_pharmacokinetics.png`: Plasma IV vs. Oral $C_p - t$ curves, multi-organ biodistribution, and 7-day steady-state accumulation.
5. `fig_task5_cyp_ddi_mbi.png`: Pre-incubation activity loss, clinical Midazolam dynamic DDI PK curves, and 2D FDA regulatory risk matrix.
6. `fig_task6_asd_supersaturation.png`: Flory-Huggins phase envelopes, Gordon-Taylor $T_g$ curves, and non-sink "Spring-and-Parachute" dissolution profiles.
7. `fig_task7_qsp_immuno_oncology.png`: Simeoni TGI 4-arm tumor trajectories, $\Delta\text{Bliss}$ synergy surface, and 50-patient Kaplan-Meier PFS curves.
8. `fig_task8_adc_multiscale.png`: Discrete DAR distributions, HIC chromatograms, lysosomal cleavage flux, and bystander radial diffusion contours.
9. `fig_task9_cryoem_allostery.png`: Latent manifold $z_1-z_2$ projections, MSM free energy opening barrier, and 2D PRS allosteric coupling matrix.
10. `fig_task10_rna_targeted_cadd.png`: RNA base-pair probability heatmap, thermodynamic cycle energy bars, and Exon Inclusion % dose-response curves.

---

### 4. MASTER BILINGUAL TREATISES & REPOSITORY COMPLETION
Generate two monumental, publication-grade academic treatises in the project root:
- **`AI4PHARM_DECADE_TREATISE_ZH.md`** (Comprehensive Chinese Master Thesis)
- **`AI4PHARM_DECADE_TREATISE_EN.md`** (Comprehensive English Master Thesis)

Covering:
- Foundational pharmacology of all 10 translational dimensions.
- Explicit mathematical derivations of all differential and algebraic systems.
- Honest boundary demarcations: What constitutes validated in-silico physics vs. where empirical in-vitro/in-vivo assay verification remains irreplaceable.

Update root `README.md` to establish the complete 10-Task Decade Architecture with master tables, interactive navigation, and reproduction commands.

Stage all code, data, reports, and figures, execute automated git commit and push:
```bash
git add .
git commit -m "feat(pantheon): release complete 10-dimensional AI4Pharm translational developability suite"
git push origin main